brand logo

Am Fam Physician. 2025;111(5):465-466

Author disclosure: No relevant financial relationships.

Zuranolone (Zurzuvae) is an oral medication labeled for the treatment of postpartum depression in adults.1 It is a neuroactive steroid gamma-aminobutyric acid (GABA) type A receptor positive modulator, which enhances the inhibitory effects of GABA at the synaptic GABA type A receptor.

DrugDosageDose formCost of full course*
Zuranolone (Zurzuvae)50 mg once daily in the evening for 14 daysCapsules: 20 mg, 25 mg, 30 mg$19,000
Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Continue Reading

More in AFP

Copyright © 2025 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.